Hyperthermic intraperitoneal chemotherapy in ovarian cancer: first, do no harm

被引：1
|
作者：
Chiva, Luis [1 ]
Vergote, Ignace [2 ]
机构：
[1] Clin Univ Navarra, Dept Ginecol & Obstet, Madrid, Spain
[2] Katholieke Univ Leuven, Leuven Canc Inst, Dept Gynecol & Obstet, Gynecol Oncol, Leuven, Belgium
来源：
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2024年 / 34卷 / 01期
关键词：
Ovarian Cancer; Surgery; Medical Oncology;
D O I：
10.1136/ijgc-2023-005148
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：10 / 11
页数：2
相关论文
共 50 条
  • [41] Hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) in ovarian cancer. Importance and current trials
    Keyver-Paik, M. -D.
    Abramian, A.
    Maass, N.
    Kuhn, W.
    GYNAKOLOGE, 2015, 48 (07): : 549 - 552
  • [42] Hyperthermic Intraperitoneal Chemotherapy (HIPEC) as Primary Treatment of Ovarian Cancer: A Review of the Current Literature
    Zirak-Schmidt S.
    Verwaal V.J.
    Indian Journal of Gynecologic Oncology, 2018, 16 (3)
  • [43] A critical appraisal of hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of advanced and recurrent ovarian cancer
    Chiva, Luis M.
    Gonzalez-Martin, Antonio
    GYNECOLOGIC ONCOLOGY, 2015, 136 (01) : 130 - 135
  • [44] Hyperthermic intraperitoneal chemotherapy in epithelial ovarian cancer: current evidence-based indications
    Pareja, Rene
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 (05) : 841 - 842
  • [45] Is it the right moment to include hyperthermic intraperitoneal chemotherapy as standard in ovarian cancer management? A reappraisal
    Samartzis, Konstantinos
    Thomakos, Nikolaos
    Liontos, Michael
    Kollia, Dimitra
    Malakasis, Anastasios
    Haidopoulos, Dimitrios
    Bamias, Aristotelis
    Rodolakis, Alexandros
    Loutradis, Dimitrios
    JOURNAL OF BUON, 2018, 23 : S19 - S23
  • [46] Survival Outcomes after Hyperthermic Intraperitoneal Chemotherapy for a First Ovarian Cancer Relapse: A Systematic Evidence-Based Review
    Classe, Jean-Marc
    Asselain, Bernard
    Campion, Loic
    Berton, Dominique
    Frenel, Jean-Sebastien
    Lecuru, Fabrice
    Ferron, Gwenael
    Gladieff, Laurence
    Bourgin, Charlotte
    Loaec, Cecile
    CANCERS, 2022, 14 (01)
  • [47] Hyperthermic intraperitoneal chemotherapy (HIPEC) is cost-effective in the management of primary ovarian cancer
    Behbakht, Kian
    Cohn, David E.
    Straughn, J. Michael, Jr.
    GYNECOLOGIC ONCOLOGY, 2018, 151 (01) : 4 - 5
  • [48] The Role of Secondary Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy in Recurrent Ovarian Peritoneal Carcinomatosis
    Ozcan, Pirilti
    Duzgun, Ozgul
    JOURNAL OF PERSONALIZED MEDICINE, 2024, 14 (07):
  • [49] Comparative Survival Outcomes of Hyperthermic Intraperitoneal Chemotherapy, Intraperitoneal Chemotherapy and Intravenous Chemotherapy for Primary Advanced Ovarian Cancer: A Network Meta-Analysis
    Tang, Qin
    Huang, Mao
    Zhang, Jing
    Huang, Zhen
    Wang, Linlian
    Gong, Zhengxin
    Tang, Liangdan
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (03)
  • [50] Intraperitoneal chemotherapy in ovarian cancer
    Hofstra, LS
    de Vries, EGE
    Mulder, NH
    Willemse, PHB
    CANCER TREATMENT REVIEWS, 2000, 26 (02) : 133 - 143
12345